RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...
The FDA approved a new injected version of the cancer immunotherapy drug Keytruda. With injections, patients need only an hour total for treatment, while Keytruda infusion may require two hours.
Sichan Kelun-Biotech Biopharmaceutical’s sac-TMT (sacituzumab tirumotecan) has posted positive results in a late-stage trial in non-small cell lung cancer (NSCLC). During the Phase III OptiTROP-Lung05 ...
First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback